CYP2C19 and depressive symptom measurement: Two studies in the Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) also failed to identify any consistent associations between CYP2C19 genetic variations and clinical response or tolerance [25,26], which contradicts our findings to an extent.